Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 CAD | -0.27% | -7.92% | -30.73% |
04-08 | Top Premarket Decliners | MT |
04-08 | Eupraxia Pharmaceuticals Inc.(NasdaqCM:EPRX) added to NASDAQ Composite Index | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 133M 97.27M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.3% |
1 day | -0.27% | ||
1 week | -7.92% | ||
Current month | -12.47% | ||
1 month | -8.82% | ||
3 months | -28.46% | ||
6 months | -27.77% | ||
Current year | -30.73% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 12-07-22 | |
Bruce G. Cousins
DFI | Director of Finance/CFO | 63 | 21-05-02 |
Amanda Malone
CTO | Chief Tech/Sci/R&D Officer | - | 12-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Geyer
BRD | Director/Board Member | 61 | 13-01-13 |
John Montalbano
FOU | Founder | 59 | 11-12-31 |
Richard Glickman
BRD | Director/Board Member | 65 | 21-03-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 3.72 | -0.27% | 16 422 |
24-04-26 | 3.73 | -4.36% | 15,050 |
24-04-25 | 3.9 | -0.76% | 6,000 |
24-04-24 | 3.93 | -0.76% | 28,910 |
24-04-23 | 3.96 | -1.98% | 32,606 |
Delayed Quote Toronto S.E., April 29, 2024 at 02:38 pm
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.73% | 97.06M | |
+2.01% | 42.75B | |
+47.70% | 41.61B | |
+12.37% | 41.34B | |
-8.83% | 26.59B | |
+6.48% | 25.49B | |
-22.99% | 18.12B | |
+30.48% | 12.24B | |
-2.05% | 11.76B | |
+8.48% | 11B |
- Stock Market
- Equities
- EPRX Stock